nNO by NIOX®

New nasal NO (nNO) application with NIOX VERO®

nNO is a sensitive and specific marker for Primary Ciliary Dyskinesia (PCD)

Diagnosis of PCD is often delayed or missed completely

One study reported that **70%** of patients had over **50** appointments before diagnosis was made[2].



What is the role of nasal Nitric Oxide (nNO)?

- nNO has been shown to be decreased in patients with PCD.
- Measurement of nNO can assist in the identification of cases of PCD according to ERS guidelines[3].
- Effective screening of patients with low risk can rule out non PCD cases and avoid further invasive and expensive confirmatory tests, whilst not missing true cases.

The only CE marked nNO device with documented clinical data for differentiating patients with PCD from healthy individuals

From the market leader in FeNO* testing

NIOX VERO® nNO application provides a non-invasive and cost-efficient way to differentiate patients with PCD from healthy individuals[4].

- In a multi-centre, non-randomised study of 152 subjects ≥5 years with known PCD (47) vs. age matched healthy controls (105), NIOX VERO nNO was shown to be an effective screening tool between the two groups[4].
- Subjects completed at least two successful nNO measurements from one nostril using either passive tidal breathing sampling method (TB-nNO) or expiration against resistance method (ER-nNO).
- The obtained cut-off values demonstrated that both TB-nNO (171 ppb) and ER-nNO (356 ppb) methods in NIOX VERO can be used in children and adult patients as part of the diagnostic work-up of PCD

NIOX VERO is the only CE marked nNO device supported with clinical evidence that delivers the following:

- The only fully portable device for nNO measurement
- Ease of use
- Patient facing display
- Two options for measuring, either tidal measurement or during exhalation against a resistor
- 30 second aspiration time
- The only CE marked nNO device with documented clinical data for differentiating patients with PCD from healthy individuals

Contact your local representative.
Visit niox.com for more information.

IMPORTANT INFORMATION REGARDING NIOX VERO®

NIOX VERO quantitatively measures Nitric Oxide in human breath (Fractional exhaled Nitric Oxide, FeNO) and nasal Nitric Oxide (nNO) in the aspirated air from the nasal cavity.
nNO - Nasal Nitric Oxide has been shown to be decreased in patients with Primary Ciliary Dyskinesia (PCD), and measurement of nNO can assist in the identification of cases of PCD according to ERS guidelines[3]. Measurement of nNO with the NIOX VERO Nasal Measurement Mode is non-invasive, simple, safe and repeatable in patients age 5 and above when measured according to the NIOX VERO Nasal Measurement Mode User Manual. Suspected cases of PCD following screening with nNO should be confirmed according to published recommendations for PCD diagnosis and management.

REFERENCES: 1. Primary Ciliary Dyskinesia. Genetics Home Reference, National Library of Medicine. https://ghr.nlm.nih.gov/condition/primary-ciliary-dyskinesia#. **2.** Sommer JU, Schäfer K, Omran H, Olbrich H, Wallmeier J, Blum A, Hörmann K, Stuck BA ENT manifestations in patients with primary ciliary dyskinesia: prevalence and significance of otorhinolaryngologic co-morbidities. Eur Arch Otorhinolaryngol. 2011 Mar; 268(3):383-8. **3.** Lucas JS, Barbato A, Collins SA, et al. European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia. Eur Respir J 2017; 49: 1601090 **4.** Circassia clinical study AER-051. Data on file 2017.

*Fractional exhaled nitric oxide

NicheMedical
Solutions in Respiratory Care & Diagnosis
Telephone 1300 136 855 Facsimile 1300 664 204
Email: info@nichemedical.com.au
www.nichemedical.com.au